LB 230 — Adopt the Kratom Consumer Protection Act, regulate nitrous oxide, and change the Uniform Controlled Substances Act

7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole;

-6- LB230 LB230 2025 (9) Mescaline;

-18- LB230 LB230 2025 (17) Thiophene analog of phencyclidine.

2-thienyl2- thienyl analog of phencyclidine;

3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran; dibenzo(b,d)pyran;

1-(1-phenylcyclohexyl)-1-(1-phenylcyclohexyl)-pyrrolidine; pyrrolidine;

(27) Any material, compound, mixture, or preparation containing any quantity of synthetically produced cannabinoids as listed in subdivisions (A) through (L) of this subdivision, including their salts, isomers, -19- LB230 LB230 2025 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs, unless specifically excepted elsewhere in this section.

Any compound containing a 3-(1-3-(1-naphthoyl)indole naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl,piperidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;

Any compound containing a 1 H-indol-3-H-indol-3-yl-(1- yl-(1-naphthyl)methanenaphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, -20-cycloalkylmethyl, -7- LB230 LB230 2025 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl,piperidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;

Any compound containing a 3-(1-3-(1-naphthoyl)pyrrole naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl,piperidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;

Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-1- pyrrolidinyl)methyl,(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;

Any compound containing a 3-3-phenylacetylindole phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl,piperidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;

Any compound containing a 2-(3- hydroxycyclohexyl)phenol structure with substitution at the 5-position of -21- LB230 LB230 2025 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl,1- 1-(N-methyl-2-(N-methyl-2-piperidinyl)methyl, pyrrolidinyl)methyl,1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,1-(N- methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not substituted in or on any of the listed ring systems to any extent;

Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-1-(N-methyl-2-piperidinyl)methyl, piperidinyl)methyl,1- 1-(N-methyl-2-pyrrolidinyl)methyl,(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-1-(N-methyl-3-morpholinyl)methyl, morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;

Any compound containing a 3-adamantoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,1- 1-(N-methyl-3-(N-methyl-2-pyrrolidinyl)methyl, morpholinyl)methyl,1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;

Any compound containing a 3- tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-1-(N-methyl-2- methyl-2-piperidinyl)methyl,piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-1-(N-methyl-2-pyrrolidinyl)methyl, pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;

Any compound containing a 1-indole-3-1-indole-3-carboxamide -22- LB230 LB230 2025 carboxamide structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-1-(N-methyl-2-piperidinyl)methyl, piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-1- pyrrolidinyl)methyl,(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxamide group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1-mapthyl,1- mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;

Any compound containing a 1-indole-3-1-indole-3-carboxylate carboxylate structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-1-(N-methyl-2-piperidinyl)methyl, piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-1- pyrrolidinyl)methyl,(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxylate group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1-mapthyl,1- mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;

(28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1- yl]-1-phenylpropan-2-ol,phenylpropan-2-ol, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such -23-isomers, esters, -8- LB230 LB230 2025 isomers, esters, ethers, and salts is possible within the specific chemical designation;

(i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known as 2C-C2C- C or 2,5-Dimethoxy-4-chlorophenethylamine;

-24- LB230 LB230 2025 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;

25B-25B-NBOMe NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;

25I-25I-NBOMe NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;

or 25C-NBOMe25C- NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;

(xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4- -25- LB230 LB230 2025 yl)ethanamine, which is also known as 2C-B-FLY;

(xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-tetrahydrobenzo[1,2-b:4,5- b:4,5-b']difuran-4-yl)-2-aminoethane,b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-2C-B-FLY-NBOMe; NBOMe;

(xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, which is also known as bromo-benzodifuranylisopropylamine or bromo-bromo-dragonFLY; dragonFLY;

(xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known as 5-APDB;5- APDB;

(xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-5-dimethoxy-a- dimethoxy-a-methylphenethylamine;methylphenethylamine;

(xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as 4-methyl-2,5-dimethoxy-amethylphenethylamine;4- methyl-2,5-dimethoxy-amethylphenethylamine;

-9- LB230 LB230 2025 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;

(xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine,N- ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;

and -26- LB230 LB230 2025 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which is also known as N-hydroxyMDA;

(A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-5-MeO-DALT; DALT;

(B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-4-AcO-DMT DMT or OAcetylpsilocin;

(C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-4-HO-MET; HO-MET;

(D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-4-HO-DIPT; HO-DIPT;

(E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as 5-MeOMiPT;5- MeOMiPT;

(F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-5-MeO-DMT; DMT;

(G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-5-MeO- MeO-DiPT;DiPT;

-27- LB230 LB230 2025 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;

or (B) Unless listed in another schedule, any substance which contains any quantity of any material, compound, mixture, or structure, other than bupropion, that is structurally derived by any means from 2-2-aminopropan-1-one aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:

(1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5- yl)amino]heptanoic acid, including its salts, isomers, and salts of -28- LB230 LB230 2025 isomers;

or 4,5-4,5-dihydro-5- dihydro-5-phenyl-2-oxazolamine;phenyl-2-oxazolamine;

alpha-alpha-aminopropiophenone; aminopropiophenone;

2-aminopropiophenone;2- aminopropiophenone;

alpha-alpha-N- N-methylaminopropiophenone;methylaminopropiophenone;

N-methylcathinone;N- methylcathinone;

-10- LB230 LB230 2025 (7) N,N-dimethylamphetamine;

and (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5-yl)carbamimidate),ium-5- yl)carbamimidate), including its salts, isomers, and salts of -29- LB230 LB230 2025 isomers.

-30- LB230 LB230 2025 (2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent to or identical with any of the substances referred to in subdivision (1) of this subdivision, except that these substances shall not include the isoquinoline alkaloids of opium;

(11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl -31- LB230 LB230 2025 butane;

(12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-2-methyl-3-morpholino-1,1-diphenylpropane- diphenylpropane-carboxyliccarboxylic acid;

(17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-ethyl-4-phenylpiperidine-4-carboxylate; carboxylate;

(18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-1-methyl-4-phenylpiperidine-4-carboxylic carboxylic acid;

-11- LB230 LB230 2025 (27) Levo-alphacetylmethadol which is also known as levo-alpha- acetylmethadol, levomethadyl acetate, and LAAM;

-32- LB230 LB230 2025 (3) Methamphetamine, its salts, isomers, and salts of its isomers;

Phenyl-2-propanone;Phenyl-2- propanone;

4-anilino-N-phenethylpiperidine -33- LB230 LB230 2025 (ANPP);

-34- LB230 LB230 2025 (10) Lysergic acid amide;

(22) Any compound, mixture, or preparation containing amobarbital, -12- LB230 LB230 2025 secobarbital, pentobarbital, or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule;

(+/-)-2-(2-chlorophenyl)-2-(methylamino)-(+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone; cyclohexanone;

2-(ethylamino)-2-(2-thienyl)-2-(ethylamino)-2-(2-thienyl)-cyclohexanone. cyclohexanone.

Trade or other names for zolazepam shall include, but are -35- LB230 LB230 2025 not limited to:

4-(2-fluorophenyl)-6,8-dihydro-1,3,8-4-(2- trimethylpyrazolo-(3,4-e)fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one,(1,4)-diazepin-7(1H)- one, and flupyrazapon.

and (2) Any material, compound, mixture, or preparation containing any -36- LB230 LB230 2025 of the following narcotic drug or its salts, as set forth below:

(4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-(3-beta,17-beta-dihydroxy-5-alpha-androst-1-ene); ene);

(5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-(3-alpha,17-beta-dihydroxy-5-alpha-androst-1-ene); ene);

(11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-(7-alpha,17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3- hydroxyandrost-4-en-3-one);one);

(14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-(7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3- en-3-one);one);

(16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-(4-chloro-17-beta-hydroxy-17-alpha- alpha-methyl-androst-1,4-dien-3-one);methyl-androst-1,4-dien-3-one);

(17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-(17-alpha-methyl-5-alpha-androst-2-en-17- -37-beta-ol) LB230 LB230 2025 en-17-beta-ol) (a.k.a.

(20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-(17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3- androstan-3-one);one);

(2-formyl-17-alpha-methyl-11-(2-formyl-17-alpha-methyl-11-alpha,17- alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);beta-dihydroxyandrost-1,4-dien-3-one);

(24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-(17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-furazan); furazan);

-13- LB230 LB230 2025 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;

(27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-(4,17-beta-dihydroxy-estr-4-en-3-one); one);

(28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-(17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one); one);

(29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-(17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one); one);

(30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-(17-alpha-methyl-17-beta-hydroxyandrost-1,4-dien-3- dien-3-one);one);

(31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-(17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-ene); ene);

(32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-(2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-beta- beta-ol-3-one);ol-3-one);

(33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-(1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-one); one);

-38- LB230 LB230 2025 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;

(37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-(17-alpha-methyl-4-hydroxy-17- hydroxy-17-beta-hydroxyestr-4-en-3-one);beta-hydroxyestr-4-en-3-one);

(38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-(17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-dien-3- dien-3-one);one);

(40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-(17-alpha-methyl-17-beta-hydroxyandrost-4-en-3- en-3-one);one);

(41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-(7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-en-3- en-3-one);one);

(42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-(17-beta-hydroxy-17- hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one)alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a.

'17-alpha-'17-alpha-methyl-1- methyl-1-testosterone');testosterone');

(48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-(estra-4,9(10)-diene-3,17-dione); dione);

(51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-17-alpha-diethyl-17-beta-hydroxygon-4-en-3- en-3-one);one);

(53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-(17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-one); one);

(54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-(17-alpha-methyl-17-beta-hydroxyestr-4-en-3-one); one);

(55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]- -39- LB230 LB230 2025 androstan-3-one);

(56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-(17-alpha-methyl-4,17-beta-dihydroxyandrost-4-en-3-one); en-3-one);

(57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-(17-alpha-methyl-2-hydroxymethylene-17-beta-hydroxy-[5- hydroxy-[5-alpha]-androstan-3-one);alpha]-androstan-3-one);

(58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-(17-beta-hydroxy-5-alpha-androstano[3,2-c]pyrazole); c]pyrazole);

(59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-(17-alpha-methyl-17-beta-hydroxy-[5-alpha]-androst-2- androst-2-eno[3,2-c]-pyrazole);eno[3,2-c]-pyrazole);

(60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-(17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-one); one);

(61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic oic acid lactone);

(73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17 beta-ol;beta- ol;

(75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-beta-hydroxy-androst-4-en-3,11-dione; dione;

-40- LB230 LB230 2025 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;

Some other names for dronabinol are (6aR-(6aR-trans)-6a,7,8,10a- trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzotetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.(-)-delta-9- -14- LB230 LB230 2025 (trans)-tetrahydrocannabinol.

-41- LB230 LB230 2025 (8) Diazepam;

-42- LB230 LB230 2025 (39) Nimetazepam;

(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the -43- LB230 LB230 2025 central nervous system, including their salts, isomers, whether optical, position, or geometric, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

-15- LB230 LB230 2025 (4) Mazindol;

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances substance, including their its -44- LB230 LB230 2025 salts:

(2) The following drug products containing ephedrine, its salts, optical isomers, and salts of such optical isomers, are excepted from subdivision (g)(1)(g) (1) of Schedule IV if they (A) are stored behind a counter, in an area not accessible to customers, or in a locked case so that a customer needs assistance from an employee to access the drug product;

and (E) are not marketed, advertised, or represented in any manner for the indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or -45- LB230 LB230 2025 high, heightened sexual performance, or increased muscle mass:

(c) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant -46- LB230 LB230 2025 effect on the central nervous system, including its salts, isomers, and salts of isomers:

-16- LB230 LB230 2025 (2) Ganaxolone;

Tax amnesty shall not be available for any person that is under civil or criminal audit, investigation, or prosecution for unreported or delinquent taxes by this state or the United States Government on or -47- LB230 LB230 2025 before April 16, 2004.

Any amount that would otherwise be deposited in the Department of Revenue Enforcement Fund that is in excess of the five-five-hundred-thousand-dollar hundred-thousand-dollar limitation shall be deposited in the General Fund.

(c) For fiscal years after fiscal year 2005-06, twenty percent of all proceeds received during the previous calendar year due to the efforts of auditors and investigators hired pursuant to subdivision (5)(5)(b) (b) of this section, not to exceed seven hundred fifty thousand dollars, shall be deposited in the Department of Revenue Enforcement Fund for -48- LB230 LB230 2025 purposes of employing investigators and auditors or continuing such employment for purposes of increasing enforcement of the act.

For the report due April 1, 2005, the report shall include (i) the amount of revenue obtained as a result of the tax amnesty program broken down by tax program, (ii) the amount obtained from instate taxpayers and from out-of-out-of-state state taxpayers, and (iii) the amount obtained from individual taxpayers and from business enterprises.

The Department of Revenue Enforcement Fund shall include any money credited to the fund (a) under section 77-2703, and such money -49- LB230 LB230 2025 shall be used by the Department of Revenue to defray the costs -17- LB230 LB230 2025 incurred to implement Laws 2019, LB237, (b) under the Mechanical Amusement Device Tax Act, and such money shall be used by the department to defray the costs incurred to implement and enforce Laws 2019, LB538, and any rules and regulations adopted and promulgated to carry out Laws 2019, LB538, (c) under section 77-2906, and such money shall be used by the Department of Revenue to defray the costs incurred to implement Laws 2020, LB310, (d) under the Kratom Consumer Protection Act, and such money shall be used by the Department of Revenue to defray the costs incurred to administer the act, and (e) (d) under section 77-3,124.

-50--18-